Alivus Life Sciences Ltd
Alivus Life Sciences Ltd (ALIVUS) last traded at ₹1,348, a market capitalisation of ₹16,551 crore, on a P/E of 26.6. Over the past 52 weeks the stock has ranged between ₹819 and ₹1,418. Alivus Life Sciences Ltd last reported results for the quarter ended Jun 2026, with sales of ₹640 crore and net profit of ₹160 crore. The next scheduled event is an analyst meet on 28 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.
Alivus Life Sciences Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Alivus Life Sciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹640 cr, up 6.3% from ₹602 cr a year earlier. Net profit was ₹160 cr, up 31.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 |
| Expenses | 373 | 452 | 451 | 430 | 409 | 442 | 475 | 429 |
| Operating profit | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 212 |
| OPM % | 27% | 30% | 31% | 29% | 30% | 34% | 31% | 33% |
| Other income | 9 | 10 | 10 | 9 | 15 | -12 | 23 | 22 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 15 | 15 | 16 | 17 | 18 | 20 | 20 | 21 |
| Profit before tax | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 |
| Tax % | 25% | 26% | 26% | 25% | 25% | 24% | 25% | 25% |
| Net profit | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 |
| EPS (₹) | 7.78 | 11.18 | 11.58 | 9.91 | 10.60 | 12.25 | 13.25 | 13.04 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Alivus Life Sciences Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 1,885 | 2,123 | 2,161 | 2,283 | 2,387 | 2,552 | 2,590 |
| Operating profit | 592 | 617 | 643 | 675 | 684 | 798 | 837 |
| OPM % | 31% | 29% | 30% | 30% | 29% | 31% | 32% |
| Net profit | 352 | 419 | 467 | 471 | 486 | 564 | 603 |
| EPS (₹) | 358.74 | 34.17 | 38.11 | 38.43 | 39.63 | 45.99 | 49.14 |
TTM is the trailing twelve months to the most recent quarter.
Alivus Life Sciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- 6%
- 3 Years
- 6%
- TTM
- 8%
- 10 Years
- %
- 5 Years
- 9%
- 3 Years
- 6%
- TTM
- 25%
- 10 Years
- %
- 5 Years
- 15%
- 3 Years
- 30%
- 1 Year
- 41%
- 10 Years
- %
- 5 Years
- 21%
- 3 Years
- 19%
- Last Year
- 18%
Alivus Life Sciences Ltd shareholding pattern
Promoters held 74.87% at Jun 2026, broadly unchanged since Jun 2025. FIIs 5.54% and DIIs 7.18%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 74.99% | 74.94% | 74.91% | 74.91% | 74.87% | 74.87% |
| FIIs | 7.85% | 6.74% | 6.57% | 6.42% | 6.84% | 5.08% | 5.30% | 5.54% |
| DIIs | 4.16% | 4.86% | 5.19% | 5.62% | 5.47% | 7.13% | 7.27% | 7.18% |
| Public | 12.99% | 13.40% | 13.25% | 13.03% | 12.79% | 12.89% | 12.55% | 12.42% |
| No. of shareholders | 1,43,960 | 1,46,840 | 1,41,977 | 1,38,500 | 1,35,643 | 1,32,748 | 1,27,969 | 1,25,559 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Alivus Life Sciences Ltd events
The next scheduled event is an analyst meet on 28 Aug 2026.
- Analyst meetIntimation of upcoming investor/analyst meetings
- Record dateRecord date for final dividend of Rs. 5.00 per share
- AGM15th Annual General Meeting, including final dividend approval
See the full results calendar for every Indian company reporting in the next 30 days.
Alivus Life Sciences Ltd corporate filings
- Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst MeetingsCompany Updatelow impact
Cruxal's analysis: Alivus Life Sciences Ltd has issued a formal intimation regarding an upcoming…
Read the full analysis - Enclosed please find herewith Press Release with respect to Acquisition.Company Updatehigh impact
Cruxal's analysis: Alivus Life Sciences Limited has announced the acquisition of a 76% majority stake in…
Read the full analysis - Enclosed please find herewith intimation pursuant to Regulation 30 of SEBI (LODR), 2015 with respect to acquisition.Company Updatemedium impact
Cruxal's analysis: Alivus Life Sciences Limited has announced the acquisition of a 76% controlling stake in…
Read the full analysis - Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst MeetingCompany Updatelow impact
Cruxal's analysis: Alivus Life Sciences Ltd has filed an intimation regarding a scheduled meeting with…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Alivus Life Sciences Ltd has published a newspaper advertisement regarding the notice of…
Read the full analysis - Business Responsibility and Sustainability Reporting (BRSR)Otherslow impact
Cruxal's analysis: Alivus Life Sciences Ltd has submitted its Business Responsibility and Sustainability…
Read the full analysis - Reg. 34 (1) Annual Report.Otherslow impact
Cruxal's analysis: Alivus Life Sciences Ltd has submitted its Integrated Annual Report for the financial…
Read the full analysis - Notice Of 15Th Annual General Meeting Of The Company For FY 2025-26 As Required Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015AGM/EGMlow impact
Cruxal's analysis: Alivus Life Sciences Limited has scheduled its 15th Annual General Meeting for September…
Read the full analysis - Enclosed please find herewith details of investor meet.Company Updatelow impact
Cruxal's analysis: Alivus Life Sciences Ltd has filed an intimation regarding an upcoming investor meet. The…
Read the full analysis - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationCompany Updatelow impact
Cruxal's analysis: Alivus Life Sciences Ltd has issued an intimation regarding an upcoming analyst and…
Read the full analysis - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptCompany Updatehigh impact
Cruxal's analysis: Alivus Life Sciences reported Q1 FY27 revenue of 640 crore, a 6.4% YoY growth, driven by…
Read the full analysis - Newspaper Advertisement for 15th Annual General Meeting (AGM)Company Updatelow impact
Cruxal's analysis: Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has issued a…
Read the full analysis - Intimation of 15th Annual General Meeting and Record date.AGM/EGMlow impact
Cruxal's analysis: Alivus Life Sciences Limited has scheduled its 15th Annual General Meeting for September…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Alivus Life Sciences Ltd
Cruxal reads every Alivus Life Sciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.